Evidence map›Paper›PMID 34557847›Full record

ReviewThe Lancet regional health. Europe2021

Optimising antimicrobial use in humans - review of current evidence and an interdisciplinary consensus on key priorities for research.

Esmita Charani, Martin McKee, Raheelah Ahmad, Manica Balasegaram, Candice Bonaconsa, Gemma Buckland Merrett, Reinhard Busse, Vanessa Carter, Enrique Castro-Sanchez, Bryony D Franklin and 18 more

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in The Lancet regional health. Europe, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 64 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
64citing papers in PubMed, 3 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

64 citing papers in PubMed, 3 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Trial
  5. Article
  6. Article
  7. Article
  8. Review
  9. Review
  10. Systematic review of implementing stewardship activities to promote appropriate antimicrobial use.Antimicrobial stewardship & healthcare epidemiology : ASHE · 2026
    Review
  11. Article
  12. Article
  13. Article
  14. Review
  15. Article
  16. Article
  17. Article
  18. Review
  19. Article
  20. Article

4 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

28 authors.

Esmita CharaniNational Institute for Health Research Health Protection Research Unit in Healthcare Associated Infections and Antimicrobial Resistance, Imperial College London, UK.
Martin McKeeLondon School of Hygiene and Tropical Medicine, London, UK.
Raheelah AhmadSchool of Health Sciences City, University of London, UK.
Manica BalasegaramThe Global Antibiotic Research and Development Partnership, Geneva, Switzerland.
Candice BonaconsaDivision of Infectious Diseases & HIV Medicine, Department of Medicine, University of Cape Town, South Africa.
Gemma Buckland MerrettDrug-Resistant Infections Priority Programme,Wellcome Trust, London, UK.
Reinhard BusseTechnische Universität Berlin, Berlin, Germany.
Vanessa CarterStanford University Medicine X e-Patient Scholars Program 2017, Health Communication and Social Media South Africa, Africa CDC Civil Society Champion for AMR.
Enrique Castro-SanchezNational Institute for Health Research Health Protection Research Unit in Healthcare Associated Infections and Antimicrobial Resistance, Imperial College London, UK.
Bryony D FranklinUniversity College London School of Pharmacy, London, UK.
Pantelis GeorgiouDepartment of Electrical and Electronic Engineering, Faculty of Engineering, Imperial College London, London, UK.
Kerri Hill-CawthorneNational Institute for Health Research Health Protection Research Unit in Healthcare Associated Infections and Antimicrobial Resistance, Imperial College London, UK.
William HopeDepartment of Molecular and Clinical Pharmacology, University of Liverpool, UK.
Yuichi ImanakaDepartment of Healthcare Economics and Quality Management, Graduate School of Medicine, Kyoto University, Kyoto, Japan.
Andrew KambuguInfectious Diseases Institute, Makerere University College of Health Sciences, Kampala, Uganda.
Andrew Jm LeatherKing's Centre for Global Health and Health Partnerships, School of Population Health and Environmental Sciences, King's College London, London, UK.
Oluchi MbamaluDivision of Infectious Diseases & HIV Medicine, Department of Medicine, University of Cape Town, South Africa.
M McLeodNational Institute for Health Research Health Protection Research Unit in Healthcare Associated Infections and Antimicrobial Resistance, Imperial College London, UK.
Marc MendelsonDivision of Infectious Diseases & HIV Medicine, Department of Medicine, University of Cape Town, South Africa.
Mirfin MpunduEcumenical Pharmaceutical Network, Nairobi, Kenya.
Timothy M RawsonNational Institute for Health Research Health Protection Research Unit in Healthcare Associated Infections and Antimicrobial Resistance, Imperial College London, UK.
Walter RicciardiUniversità Cattolica del Sacro Cuore, Rome, Italy.
Jesus Rodriguez-ManzanoDepartment of Electrical and Electronic Engineering, Faculty of Engineering, Imperial College London, London, UK.
Sanjeev SinghDepartment of Infection Control and Epidemiology, Amrita Institute of Medical Science, Amrita Vishwa Vidyapeetham, Kochi (Kerala), India.
Constantinos TsioutisDepartment of Internal Medicine and Infection Prevention and Control, School of Medicine, European University Cyprus, Nicosia, Cyprus.
Chibuzor UcheaDrug-Resistant Infections Priority Programme,Wellcome Trust, London, UK.
Nina ZhuNational Institute for Health Research Health Protection Research Unit in Healthcare Associated Infections and Antimicrobial Resistance, Imperial College London, UK.
Alison H HolmesNational Institute for Health Research Health Protection Research Unit in Healthcare Associated Infections and Antimicrobial Resistance, Imperial College London, UK.

Funding

Wellcome Trust
6 · The paper itself

Abstract

Addressing the silent pandemic of antimicrobial resistance (AMR) is a focus of the 2021 G7 meeting. A major driver of AMR and poor clinical outcomes is suboptimal antimicrobial use. Current research in AMR is inequitably focused on new drug development. To achieve antimicrobial security we need to balance AMR research efforts between development of new agents and strategies to preserve the efficacy and maximise effectiveness of existing agents. Combining a review of current evidence and multistage engagement with diverse international stakeholders (including those in healthcare, public health, research, patient advocacy and policy) we identified research priorities for optimising antimicrobial use in humans across four broad themes: policy and strategic planning; medicines management and prescribing systems; technology to optimise prescribing; and context, culture and behaviours. Sustainable progress depends on: developing economic and contextually appropriate interventions; facilitating better use of data and prescribing systems across healthcare settings; supporting appropriate and scalable technological innovation. Implementing this strategy for AMR research on the optimisation of antimicrobial use in humans could contribute to equitable global health security.

Identifiers

PMID34557847
PMCPMC8454847

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.